TXMD NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

TherapeuticsMD Inc · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data Download investor PDF
Latest close 2.06 USD
0.0% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -3.3% below the Trend Line and sits at 54.6% of its 52-week range. The latest completed week returned 0.0%, after a -2.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 58/100 conviction, while the latest news-sentiment score is 48/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.

Setup score 40 out of 100
Latest Close 2.06 USD 24 Jul 2026
1W Return 0.0% latest completed week
4W Return -2.4% short-term follow-through
12W Return -0.5% quarterly tape
Trend Breadth 57.7% 30 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is negative, which weakens the current setup.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.0% Latest completed week; four-week move -2.4%. Indicator stack 32/45 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 58/100 conviction; expected move 76.6%. News sentiment 48/100 39 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -3.3% below the Trend Line and sits at 54.6% of its 52-week range. The latest completed week returned 0.0%, after a -2.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4812-week average 0.45

12-week confirmation

Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership10/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.48Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -2.4% over four weeks, -0.5% over 12 weeks, and 73.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W0.0%
4W-2.4%
12W-0.5%
26W-21.1%
52W73.1%
Active trend streak0 weeks
Active weeks in one year30
Trend breadth57.7%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.34Latest activity-pressure read.
Pressure change13.6%Four-week change in activity pressure.
Leadership5.82Latest relative-leadership reading.
RS change-20.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 88% Model confidence 84%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength33/100Blend of value, momentum, and quality. Underlying universe rank 68; rank 1 is best.
Value42/100Relative valuation strength. Underlying universe rank 59; rank 1 is best.
Quality41/100Profitability and accounting quality. Underlying universe rank 60; rank 1 is best.
Momentum43/100Medium-term price momentum. Underlying universe rank 58; rank 1 is best.
Growth43/100Revenue and earnings growth. Underlying universe rank 58; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
133.2x
Price divided by trailing earnings.
Price / sales
7.1x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
12.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
90.3%
Gross profit retained from each unit of revenue.
Operating margin
-137.8%
Operating profit retained from revenue.
Free-cash-flow margin
79.7%
Free cash flow generated from revenue.
Return on invested capital
-14.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
82.1%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
89.4%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.8x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

TXMD shows volatility options pressure with a 58/100 conviction score, put-call volume ratio of n/a, expected move of 76.6%, and Sharemaestro trend signal inactive.

Conviction58/100
Expected move76.6%
Put/call volume
Pressure-89
Speculation1
Volatility96
Trend agreement42
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment48/100

Weighted news tone is neutral across 39 relevant articles.

9 positive · 23 neutral · 7 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move76.6%Nearest-chain priced movement where available.
52-week drawdown-30.2%Distance below the 52-week high.
13-week volatility6.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2612 weeks finished lower.
Best week+10.6%Week of 12 Jun.
Worst week-17.2%Week of 30 Jan.
Latest week+0.0%Week of 24 Jul.

Shape of recent returns

Strong gains5
Modest gains6
Flat weeks3
Modest losses4
Sharp losses8
Recent vol6.1%13-week weekly-return volatility.
Base vol9.7%52-week weekly-return volatility.
Up/down split25/24Count of positive and negative weeks in the 52-week window.
Average skew8.1% / -5.2%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape40/100

Trend, activity pressure, participation, and risk combine to a 40/100 tape read.

 Indicator analysis43/100

Latest 12-week confirmation: trend 5/12, activity pressure 0/12, relative leadership 10/12.

Activity pressure 0.48; No reversal markers Factors38/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 52 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options49/100

TXMD shows volatility options pressure with a 58/100 conviction score, put-call volume ratio of n/a, expected move of 76.6%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 76.6% Sentiment48/100

Weighted news tone is neutral across 39 relevant articles.

TherapeuticsMD Inc. stock outperforms competitors on strong trading day Insiders50/100

No recent insider transaction evidence is stored.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20262.06 USD0.0%2.13 USD1.85 USD-0.345.82122.2KOff
17 Jul 20262.06 USD3.0%2.12 USD1.86 USD-0.324.7798.8KOff
10 Jul 20262.00 USD-5.2%2.11 USD1.87 USD-0.41-1.91195.4KOff
3 Jul 20262.11 USD0.0%2.10 USD1.89 USD-0.255.81140.0KOff
26 Jun 20262.11 USD8.2%2.09 USD1.90 USD-0.397.33168.4KOff
19 Jun 20261.95 USD-11.4%2.07 USD1.91 USD-0.49-4.65226.3KOff
12 Jun 20262.20 USD10.6%2.07 USD1.92 USD-0.5210.88615.9KOn
5 Jun 20261.99 USD-7.0%2.06 USD1.94 USD-0.823.20381.8KOff
29 May 20262.14 USD0.9%2.04 USD1.95 USD-0.876.3287.1KOn
22 May 20262.12 USD6.0%2.01 USD1.96 USD-0.958.4455.2KOn
15 May 20262.00 USD1.0%1.98 USD1.97 USD-0.963.6181.3KOn
8 May 20261.98 USD-4.3%1.96 USD1.99 USD-0.972.20166.4KOn
1 May 20262.07 USD-5.5%1.92 USD2.00 USD-0.9612.5488.5KOn
24 Apr 20262.19 USD5.8%1.89 USD2.02 USD-0.9421.0494.7KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.